Evidence map›Paper›PMID 28862644›Full record

ReviewCancers2017

Chimeric Antigen Receptor (CAR) T Cell Therapy for Malignant Pleural Mesothelioma (MPM).

Astero Klampatsa, Andrew R Haas, Edmund K Moon, Steven M Albelda

Open access · goldAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Cancers, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.

0numbers the graph read from it
0cells of the map it votes in
24citing papers in PubMed
1.8field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

24 citing papers in PubMed, 32 citations in OpenAlex.

  1. Review
  2. Review
  3. Strategies for Altering Delivery Technologies to Optimize CAR Therapy.International journal of molecular sciences · 2025
    Review
  4. Review
  5. Review
  6. Review
  7. Review
  8. Review
  9. Review
  10. Review
  11. Review
  12. Review
  13. Review
  14. Article
  15. Engineering Next-Generation CAR-T Cells for Better Toxicity Management.International journal of molecular sciences · 2020
    Review
  16. Review
  17. Article
  18. Review
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

Astero KlampatsaDivision of Pulmonary, Allergy, and Critical Care, Department of Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA. asterok@mail.med.upenn.edu.
Andrew R HaasDivision of Pulmonary, Allergy, and Critical Care, Department of Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA. Andrew.Haas2@uphs.upenn.edu.
Edmund K MoonDivision of Pulmonary, Allergy, and Critical Care, Department of Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA. Edmund.Moon@uphs.upenn.edu.
Steven M AlbeldaDivision of Pulmonary, Allergy, and Critical Care, Department of Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA. albelda@mail.med.upenn.edu.
University of Pennsylvania · US

Funding

Translational Research Support CoreP30ES013508 · NIEHS · UNIVERSITY OF PENNSYLVANIA · PI Trevor M Penning · 2006 to 2026
$35.3M
VECTOR DEVELOPMENT /PRECLINICAL TESTINGP01CA066726 · NCI · UNIVERSITY OF PENNSYLVANIA · PI HEITJAN, DANIEL FRANCIS · 1995 to 2016
$18.2M
Use of Genetically Engineered T cells Targeting Tumor Stroma to Treat Lung CancerR01CA172921 · NCI · UNIVERSITY OF PENNSYLVANIA · PI ALBELDA, STEVEN MARK · 2013 to 2017
$1.8M
Augmenting Chimeric Antibody Receptor Directed T cell Therapy for CancerK08CA163941 · NCI · UNIVERSITY OF PENNSYLVANIA · PI MOON, EDMUND K. · 2012 to 2016
$869k
NCI NIH HHS K08 CA163941NCI NIH HHS P01 CA066726NCI NIH HHS R01 CA172921NIEHS NIH HHS P30 ES013508
6 · The paper itself

Abstract

Cancer immunotherapy has now become a recognized approach to treating cancers. In addition to checkpoint blockade, adoptive T cell transfer (ACT) using chimeric antigen receptors (CARs) has shown impressive clinical outcomes in leukemias and is now being explored in solid tumors. CARs are engineered receptors, stably or transiently transduced into T cells, that aim to enhance T cell effector function by recognizing and binding to a specific tumor-associated antigen. In this review, we provide a summary of CAR T cell preclinical studies and clinical trials for malignant pleural mesothelioma (MPM), a rare, locally invasive pleural cancer with poor prognosis. We list other attractive potential targets for CAR T cell therapy for MPM, and discuss augmentation strategies of CAR T cell therapy with other forms of immunotherapy in this disease.

Indexed as

adoptive cell transferchimeric antigen receptor T cellsimmunotherapymesothelioma

Identifiers

PMID28862644
PMCPMC5615330
OpenAlexW2751695648

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.